Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clevudine + peginterferon is a combination therapy investigated for the treatment of chronic hepatitis B virus (HBV) infection. Clevudine is a nucleoside analog antiviral that inhibits HBV DNA polymerase through non-competitive inhibition by its triphosphate form, interfering with viral replication[6]. Peginterferon (specifically peginterferon alfa-2a) is a recombinant interferon conjugated to polyethylene glycol to extend its half-life; it acts as an immunomodulator by binding to type 1 interferon receptors and inducing antiviral responses in host cells[1][4]. This combination aims to enhance antiviral efficacy against HBV by targeting the virus through two distinct mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clevudine + peginterferon.